Should anti-inhibitor coagulant complex and tranexamic acid be used concomitantly?

Haemophilia

Volumn 21, Issue 6, 2015, Pages 709-714

  Valentino, L A ^a   Holme, P A ^b,c  

^a RUSH UNIVERSITY   (United States)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Anti inhibitor coagulant complex; Antifibrinolytic; Bypassing therapy; Haemophilia; Inhibitors; Tranexamic acid

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; AMINOCAPROIC ACID; RECOMBINANT BLOOD CLOTTING FACTOR 7A; THROMBIN; TRANEXAMIC ACID; BLOOD CLOTTING INHIBITOR;

ARTERIOVENOUS FISTULA; ARTICLE; BLEEDING; BLOOD CLOT LYSIS; BLOOD CLOTTING PARAMETERS; BRAIN HEMORRHAGE; COMBINATION CHEMOTHERAPY; DENTAL PROCEDURE; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG EFFICACY; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EPISTAXIS; FIBRINOLYSIS; GASTROINTESTINAL HEMORRHAGE; HEART SURGERY; HEMOPHILIA A; HEMOPHILIA B; HEMOSTASIS; HUMAN; IN VIVO STUDY; LIVER SURGERY; MAXIMUM CLOT FIRMNESS; MONOTHERAPY; ORAL CAVITY BLEEDING; ORAL VACITY BLEEDING; ORTHOPEDIC SURGERY; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; SINGLE DRUG DOSE; THROMBOCYTOPENIA; THROMBOELASTOGRAPHY; THROMBOSIS; UNSPECIFIED SIDE EFFECT; BLOOD;

BLOOD COAGULATION FACTOR INHIBITORS; HUMANS; TRANEXAMIC ACID;

EID: 84946403438     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/hae.12723     Document Type: Article

References (30)

1. Sharp HK, Mcilveen LP, Schuman N. Use of FEIBA and Amicar in the operating room- dental treatment of patient with hemophilia and high titer factor VIII inhibitors. Spec Care Dentist 1986; 6: 210-2.
2. Holmstrom M, Tran HTT, Holme P. A combined treatment with APCC (FEIBA) and tranexamic acid in patients with haemophilia A with inhibitors and in patients with acquired haemophilia A- a two centre experience. Haemophilia 2012; 18: 544-9.
3. Carr ME Jr, Alving BM. Effect of fibrin structure on plasmin-mediated dissolution of plasma clots. Blood Coag Fibrinolysis 1995; 6: 567-73.
4. He S, Blomback M, Ekman GJ, Hendner U. The role of recombinant factor FVIIa (rFVIIa) in fibrin structure in the absence of FVIII/FIX. J Thromb Haemost 2003; 1: 1215-9.
5. Berntorp E, Shapiro A. Inhibitor treatment in haemophilias A and B: summary statement for the 2006 international consensus conference. Haemophilia 2006; 12(Suppl. 6): 1-7.
6. Allen G, Aledort L. Therapeutic decision- making in inhibitor patients. Am J Hematol 2006; 81: 71-2.
7. Kruse-Jarres R. Inhibitors: our greatest challenge. Can we minimize the incidence? Haemophilia 2013; 19(Suppl. 1): 2-7.
8. Négrier C, Gomperts ED, Oldenburg J. The history of FEIBA: a lifetime of success in the treatment of haemophilia complicated by an inhibitor. Haemophilia 2006; 12(Suppl. 5): 4-13.
9. DiMichele D. Inhibitors to FVIII- epidemiology and treatment. In: Lee CA, Berntorp EE, Hoots WK eds. Textbook of Hemophilia. Malden, MA: Blackwell Publishing Ltd, 2005: 64-70.
10. White GC II, Rosendaal F, Aledort LM, Lusher JM, Rothschild C, Ingerslev J; for the Factor VIII and Factor IX Subcommittee. Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the international society of thrombosis and haemostasis. Thromb Haemost 2001; 85: 560.
11. Gomperts E, Astermark J, Gringeri A, Teitel J. From theory to practice: applying current clinical knowledge and treating strategies to the care of hemophilia A patients with inhibitors. Blood 2008; 22(Suppl. 1): S1-11.
12. Aledort L. Inhibitors in hemophilia patients: current status and management. Am J Hematol 1994; 47: 208-17.
13. Hayashi T, Tanaka I, Shima A. Unresponsiveness to factor VIII inhibitor bypassing agents during haemostatic treatment for life-threatening massive bleeding in a patient with haemophilia A and high responding inhibitor. Haemophilia 2004; 10: 397-400.
14. Teitel J, Carcao M, Lillicrap D et al. Orthopaedic surgeries in haemophilia patients with inhibitors: a practical guide to haemostatic, surgical and rehabilitative care. Haemophilia 2009; 15: 227-39.
15. Menart C, Lalain JJ, Lienhart A, Dechavanne M, Negrier C. Safety and efficacy of three arthroscopic procedures using Holmium: Yag laser in two high-responder haemophiliacs. Haemophilia 1999; 5: 278-81.
16. Scharrer I. Mutiple dental extractions with FEIBA in a patient with factor VIII inhibitor. In: Mariani G, Russo MA, Mandelli F eds. Activated Prothrombin Complex Concentrates. Managing Hemophilia with Factor VIII Inhibitor. New York: Praeger Publishers, 1982: 181.
17. Sniecinski RM, Levy JH. Bleeding and management of coagulopathy. J Thorac Cardiovasc Surg 2011; 142: 662-7.
18. Feiba Anti-Inhibitor Coagulant Complex (package insert). Westlake Village, CA: Baxter Healthcare Cooperation, 2013.
19. ®: mode of action. Haemopholia 2004; 10(Suppl. 2): 3-9.
20. Rizza CR. Inhibitors of fibrinolysis in the treatment of hemophilia. J Clin Pathol 1980; 14: 50-4.
21. Dai L, Bevan D. Stabilization of fibrin clots by activated prothrombin complex concentrate and tranexamic acid in FVIII inhibitor plasma. Haemophilia 2011; 2011: e944-8.
22. Tran HTT, Sørensen B, Rea CJ et al. Bypassing agent therapy with and without tranexamic acid in haemophilia a patients with inhibitors - an in-vivo prospective crossover study. Lancet 2013; 1: 1-10.
23. Stefanska-Windyga E, Barnan B, Crubak G, Windyga J. Safe Concurrent Use of Intravenous or Oral Tranexamic Acid and APCC in Patients with Haemophilia Complicated by High-Titer Inhibitors. PO-WE-036. Paris, France: WFH, 2012.
24. Vermylen J, Schetz J, Sermerar N, Mertens F, Verstraete M. Evidence that 'activated' prothrombin concentrates enhance platelet coagulant activity. Br J Haematol 1978; 38: 235-42.
25. Stenbjerg S, Tauris P, Skottun T, Jorgensen J. Total dental extraction in a patient with FVIII inhibitor. Thromb Res 1980; 18: 889-93.
26. Agrestini F, Solinas S, Marinelli M, Avvisati G, Badia D, Mazzucconi MG. Activated prothrombin complex concentrates in dental extractions and oral and minor surgery in hemophiliacs with high-titer inhibitor. In: Mariani G, Russo MA, Mandelli F eds. Activated Prothrombin Complex Concentrates: Managing Hemophilia with FactorVIII Inhibitor. NewYork, NY: Praeger Publishers, 1982: 168-75.
27. Négrier C, Lienhart A, Numerof R et al. SURgical interventions with FEIBA (SURF): international registry of surgery in haemophilia patients with inhibitory antibodies. Haemophilia 2013: e143-50.
28. Tjønnfjord GE, Brinch L, Gedde-Dahl T, Brosstad FR. Activated prothrombin complex concentrate (anti-inhibitor coagulant complex) treatment during surgery in patients with inhibitors to FVIII/IX. Haemophilia 2004; 10: 174-8.
29. Musso R, Cabibbo S, Cultrera D et al. APCC treatment (FEIBA) in children with haemophilia a and high levels of inhibitors to factor VIII is effective to resolve cerebral haemorrhages. Pediatr Res 1997; 41: 78.
30. Mehta R, Parameswaran R, Shapiro AD. An overview of the history, clinical practice concerns, comparative studies and strategies to optimize therapy of bypassing agents. Haemophilia 2006; 12(Suppl. 6): 54-61.